中文摘要：

目的：以改良方法在鸡胚绒膜尿囊膜（chickchorioallantoicmembrane，CAM）上接种人成神经胶质瘤U87细胞制备移植瘤，验证改良模型筛选抗肿瘤血管新生药物的有效性和可行性。方法：将鸡胚种蛋随机分为2组，分别使用传统方法与改良方法建立CAM-U87移植瘤模型；改良方法在鸡胚孵育中增加9—16h的开窗适应期，再将特制的硅胶圈放置在CAM组织-级血管的半侧；硅胶圈内接种U87细胞建立CAM—U87移植瘤模型。模型的硅胶圈内分别加入经典抗血管新生药物沙利度胺（50、100、200μg／ml）和自主研发抗血管新药G386，以DMSO为对照；体视显微镜观察肿瘤形态，H—E染色法观察瘤组织新生微血管密度（microvesseldensity，MVO），原位杂交（insituhybridization，ISH）技术检测血管标记物VEGFR2的表达。结果：成功制备改良CAM—U87细胞移植瘤，改良模型不影响CAM本身的血管生成，其瘤细胞接种成功率较传统模型显著升高[（70．00±4．226）％vs（41．25±5．154）％；t=4．314，P=0．0007]，移植瘤体积显著增大[（60．20±6．012）vs（15．97±2．403）mm3；t=6．012，P〈0．0001]。沙利度胺和G386两药均能显著抑制移植瘤组织中的血管形成，使瘤组织中MVD显著降低[沙利度胺200μg／ml时（15．85±1．15）％vs（29．80±4．16）％；t=2．49，P=0．0474]、VEGFR2表达明显减少。结论：改良方法成功制备CAM—U87移植瘤模型，经沙利度胺和G386验证，该模型对抗肿瘤血管新生药物的筛选具有良好的有效性和可行性。

英文摘要：

Objective： To modify the classical chick embryo chorioallantoic membrane （CAM） xenograft model of tu- muorigenesis and evaluate the effectiveness and feasibility of the modified model in the screening of anti-angiogenesis drugs. Methods： Fertilized chicken eggs randomized into two groups. Eggs in the classical model group were grafted with U87 human glioma cells and the anti-angiogenic activity of test drugs, thalidomide （50, 100, 200 μg/ml）, G3B6 and DMSO （ the control） was determined by following the well-established classical methods. In the modified model group, the CAM was given an additional adaptation period of 9-16 h and then grafted with U8 ceils by inoculating the cells into a sili- cone ring and then placing the ring on the half of the grade 1 vessel of the CAM. The test drugs were added into the sili- cone ring where their anti-angiogenic activity was evaluated. For both groups, the tumor morphology and the microvessel density （MVD） in the tumor tissue were examined under a stereo microscope with photos taken. Changes in the tumor his- tology was assessed by H-E staining and the expression of VEGFR2, the marker of the angiogenesis, was assessed by in si- tu hybridization. Results： The success rate of the xenograft was increased significantly without any negative effect on an- giogenesis in the CAM in the modified model as compared with the classical model （[70 ± 4. 226 ] % vs [41.25 ± 5. 154] % ; t = 4. 314, P = 0. 000 7）. The tumor volume was also significantly increased in the modified model group ascompared with thecalissical model group （ [ 60.20 ± 6. 012 ] vs [ 15.97 ± 2. 403 ] mm3 ; t = 6.012, P 〈 0.000 1 ）. Both thalidomide and G3B6 effectively inhibited the angiogenesis and reduced the MVD and VEGFR2 expression in the tumor tissue. Conclusion ： The modified xenograft CAM model of tumuorigenesis developed in this study seems superior over the classical CAM model in studying tumorigenesis and screening anti-angiogenesis drugs.